Tissue penetration of moxifloxacin into human gallbladder wall in patients with biliary tract infections

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 5, 2009, Pages

  Ober, Michael C ^a   Hoppe Tichy, Torsten ^a   Köninger, Jörg ^a   Schunter, Oliver ^b   Sonntag, Hans Günther ^c   Weigand, Markus A ^a   Encke, Jens ^a   Gutt, Carsten ^a   Swoboda, Stefanie ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Hospital Bietigheim Bissingen   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Perioperative prophylaxis; Surgery; Tissue concentration

Indexed keywords

MOXIFLOXACIN; ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; BILIARY TRACT INFECTION; CHOLECYSTECTOMY; CHOLECYSTITIS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG TISSUE LEVEL; FEMALE; GALLBLADDER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MALE; MINIMUM INHIBITORY CONCENTRATION; PERIOPERATIVE PERIOD; WOUND HEALING IMPAIRMENT; BACTERIAL INFECTION; BILIARY TRACT DISEASE; CHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; SERUM; TIME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTERIAL INFECTIONS; BILIARY TRACT DISEASES; CHOLECYSTITIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; GALLBLADDER; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; QUINOLINES; SERUM; TIME FACTORS; YOUNG ADULT;

EID: 73949100115     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp318     Document Type: Article

References (21)

1. Westphal JF, Brogard JM. Biliary tract infections: a guide to drug treatment. Drugs 1999; 57: 81-91.
2. Lubasch A, Lode H. [Antibiotic therapy in cholecystitis, cholangitis and pancreatitis]. Internist 2000; 41: 168-74.
3. Weber A, Huber W, Kamereck K et al. In vitro activity of moxifloxacin and piperacillin/sulbactam against pathogens of acute cholangitis. World J Gastroenterol 2008; 14: 3174-8.
4. Edmiston CE, Krepel CJ, Seabrook GR et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother 2004; 48: 1012-6.
5. Drusano GL, Johnson DE, Rosen M et al. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37: 483-90.
6. Wacke R, Forster S, Adam U et al. Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose. J Antimicrob Chemother 2006; 58: 994-9.
7. Wirtz M, Kleeff J, Swoboda S et al. Moxifloxacin penetration into human gastrointestinal tissues. J Antimicrob Chemother 2004; 53: 875-7.
8. Schwab D, Grauer M, Hahn EG et al. Biliary secretion of moxifloxacin in obstructive cholangitis and the non-obstructed biliary tract. Aliment Pharmacol Ther 2005; 22: 417-22.
9. Stass H, Dalhoff A. Determination of BAY 12-8039, a new 8-methoxyquinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing. J Chromatogr B Biomed Sci Appl 1997; 702: 163-74.
10. Bottcher S, von Baum H, Hoppe-Tichy T et al. An HPLC assay and a microbiological assay to determine levofloxacin in soft tissue, bone, bile and serum. J Pharm Biomed Anal 2001; 25: 197-203.
11. Goldstein EJ, Citron DM, Warren YA et al. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 2006; 50: 148-55.
12. Rink AD, Stass H, Delesen H et al. Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess. Clin Drug Investig 2008; 28: 71-9.
13. Tourmousoglou CE, Yiannakopoulou E, Kalapothaki V et al. Adherence to guidelines for antibiotic prophylaxis in general surgery: a critical appraisal. J Antimicrob Chemother 2008; 61: 214-8.
14. Gyssens IC. Preventing postoperative infections: current treatment recommendations. Drugs 1999; 57: 175-85.
15. Wise R, Andrews JM, Marshall G et al. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration. Antimicrob Agents Chemother 1999; 43: 1508-10.
16. Muller M, Stass H, Brunner M et al. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother 1999; 43: 2345-9.
17. Stass H, Kubitza D, Schuhly U. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. Clin Pharmacokinet 2001; 40 Suppl 1: 1-9.
18. Burkhardt O, Borner K, Stass H et al. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. Scand J Infect Dis 2002; 34: 898-903.
19. Sullivan JT, Woodruff M, Lettieri J et al. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemother 1999; 43: 2793-7.
20. Noel AR, Bowker KE, Macgowan AP. Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 2005; 49: 4234-9.
21. Swoboda S, Oberdorfer K, Klee F et al. Tissue and serum concentrations of levofloxacin 500 mg administered intravenously or orally for antibiotic prophylaxis in biliary surgery. J Antimicrob Chemother 2003; 51: 459-62.